|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:approvalYear
|
2023
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA59
|
|
gptkbp:brand
|
gptkb:Velsipity
|
|
gptkbp:CASNumber
|
1204669-58-8
|
|
gptkbp:chemicalClass
|
imidazole derivative
|
|
gptkbp:contraindication
|
stroke
unstable angina
severe hepatic impairment
advanced heart block
recent myocardial infarction
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:Arena_Pharmaceuticals
|
|
gptkbp:hasMolecularFormula
|
C24H23F3N2O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
etrasimod
|
|
gptkbp:indication
|
moderate to severe ulcerative colitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
S1P receptor modulator
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
hypertension
infections
bradycardia
liver enzyme elevation
|
|
gptkbp:target
|
gptkb:sphingosine-1-phosphate_receptor_1
gptkb:sphingosine-1-phosphate_receptor_4
gptkb:sphingosine-1-phosphate_receptor_5
|
|
gptkbp:usedFor
|
ulcerative colitis
|
|
gptkbp:bfsParent
|
gptkb:APD334
gptkb:Velsipity
|
|
gptkbp:bfsLayer
|
7
|